Solventum Corporation (SOLV) Financial Statements
Historical financial data — 9 statements covering FY2024–FY2025
Solventum Corp is a healthcare company developing, manufacturing, and commercializing solutions leveraging material science, data science, and digital capabilities to address customer and patient n...
Solventum Corporation's revenue increased 0.9% year over year, from $8.25B to $8.32B.
Net income increased 224.8% over the same period, from $479.0M to $1.56B.
Total debt decreased by 37.1% to $5.04B.
The debt-to-equity ratio stands at 1.00, indicating a moderate leverage profile.
Operating cash flow declined 68.9% to $369.0M.
Solventum Corporation maintains a healthy net profit margin of 18.7%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2024 | $2.02B | $237.0M | $1.17B | $381.0M | $442.0M | $14.71B | $8.30B | $3.85B |
| Q2 FY2024 | $4.10B+103.2% | $326.0M | $2.31B | $625.0M | $797.0M | $14.58B | $8.31B | $2.87B |
| Q3 FY2024 | $6.18B+50.8% | $448.0M | $3.47B | $900.0M | $966.0M | $14.74B | $8.11B | $3.19B |
| Q1 FY2025 | $2.07B-66.5% | $137.0M | $1.11B | $152.0M | $29.0M | $14.53B | $7.91B | $3.26B |
| Q2 FY2025 | $4.23B+104.4% | $227.0M | $2.29B | $367.0M | $198.0M | $15.07B | $7.82B | $3.65B |
| Q3 FY2025 | $6.33B+49.5% | $1.49B | $3.42B | $2.06B | $274.0M | $13.97B | $5.14B | $4.99B |
| Q1 FY2026 | $2.01B-68.3% | $13.0M | $1.10B | $81.0M | $-189.0M | $14.10B | $5.08B | $4.97B |
Balance Sheet Summary (Latest Period)
Total Assets
$14.29B
Total Liabilities
$9.24B
Total Equity
$5.05B
Cash & Equivalents
$878.0M
Total Debt
$5.04B
Current Assets
$3.86B
Current Liabilities
$3.14B
Retained Earnings
$1.80B